- Home
- VTGN vs BOLD Comparison
VTGN vs BOLD Comparison
Compare VTGN & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VTGN | BOLD |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.8M | 25.7M |
| IPO Year | 2014 | 2024 |
Fundamental Metrics
Financial Performance| Metric | VTGN | BOLD |
|---|---|---|
| Price | $0.64 | $1.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $0.90 | ★ $4.00 |
| AVG Volume (30 Days) | ★ 546.3K | 55.8K |
| Earning Date | 02-12-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | $124.49 | N/A |
| Revenue Next Year | $353.99 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $0.96 |
| 52 Week High | $5.14 | $1.78 |
Technical Indicators
Market Signals| Indicator | VTGN | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 49.59 | 54.72 |
| Support Level | $0.63 | $1.15 |
| Resistance Level | $0.65 | $1.19 |
| Average True Range (ATR) | 0.04 | 0.03 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 69.00 | 87.50 |
Price Performance
Historical ComparisonAbout VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.